Chamber Approves Warning on Medications That May Impair Driving Ability
The Health Commission of the Chamber of Deputies took an important step for traffic safety by approving a project that requires warnings on the labels, package inserts, and advertising materials of medications capable of affecting the ability to drive.
The measure, which aims to raise consumer awareness about the risks of combining driving and certain medications, was included as a substitute by the rapporteur, Deputy Rogéria Santos (Republicanos-BA), to Bill 877/24, authored by Deputy Juninho do Pneu (União-RJ).
“The use of medications associated with driving can significantly increase the risk of traffic accidents,” stated the rapporteur. She emphasized that the initiative will allow consumers to make safer decisions, reducing the likelihood of accidents.
-
Honda launches ‘premium Kombi’ with 7 seats cheaper than Jeep Commander, Toyota SW4, and Chevrolet Trailblazer in Brazil; for about R$ 87,000 in conversion without taxes, the Honda Freed has a 1.5 engine, hybrid option and e:HEV, CVT transmission, Honda Sensing, sliding doors, and a family package that Brazilians don’t have yet, but Japan does.
-
Without a windshield, without license plates, without headlights, and with the door tied with a rope, a truck was seized by the PRF on BR-316 using a drum as a fuel tank inside the cabin while transporting firewood in Pernambuco, and even the driver didn’t have a driver’s license.
-
Xiaomi aims to go beyond the “best electric car in the world” and is now investing in AI, realistic simulations, and 3D reconstruction to challenge Tesla in autonomous driving.
-
Suzuki sells an “economical family minivan” with 7 seats cheaper than Chevrolet Spin, Citroën Aircross, and Caoa Chery Tiggo 8 in Brazil; for about R$ 47,000 in conversion without taxes, the Ertiga has a 1.5 engine, manual or automatic transmission, CNG option, a trunk of up to 803 liters, and a family package that Brazil doesn’t have, but India does.
The proposal amends Law 6.360/76, which regulates health surveillance of medications, expanding the requirements to protect drivers and pedestrians.
The wording of the approved text was carefully adjusted to include the mandatory warnings without excessively burdening the pharmaceutical industry.
The proposal reflects the growing concern for traffic safety, especially in light of frequent reports of accidents associated with the misuse of medications that impair reflexes and attention.
Next Steps in Congress
Now, the project goes for analysis, in a conclusive manner, by the Consumer Defense and Constitution, Justice and Citizenship (CCJ) commissions. If approved in these stages, it will still need to pass a vote in the Chamber and the Senate before being sanctioned and becoming law.
Despite the progress, experts warn that the effectiveness of the measure depends not only on the adoption of the warnings but also on raising public awareness and proper enforcement.
One point that raised questions was the deadline for pharmaceutical companies to adapt to the new requirements, which will still be defined in subsequent regulation. This highlights the importance of open dialogue among government, industry, and society.
With the final approval, it is expected that the initiative will contribute to the reduction of accidents related to the use of medications and driving.

Be the first to react!